Healthcare Industry News: OrbusNeich
News Release - April 9, 2012
InspireMD Appoints Robert Ratini as Vice President of Sales and MarketingTEL AVIV, Israel, April 9, 2012 -- (Healthcare Sales & Marketing Network) -- InspireMD, Inc. (OTC BB: NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, today announced the appointment of Robert Ratini as its Vice President of Sales and Marketing. Mr. Ratini will develop and lead all global marketing strategies for InspireMD's proprietary stent system technology, MGuard™. Mr. Ratini will join InspireMD full time on June 1, 2012.
Mr. Ratini has over 20 years of experience in leadership roles in the medical device industry. He was previously Director of Marketing at OrbusNeich Medical Hoevelaken in the Netherlands. Prior to that, he served as Vice President of Global Marketing and EMEA Sales at Biosensors International, Switzerland, where he established a global sales and marketing department and led the launch of the BioMatrix™ drug eluting stent. His experience also includes positions at Abbott Vascular Europe, CardiacAssist Inc., Europe and Boston Scientific, Switzerland. He also spent 10 years at Haemonetics SA, Switzerland, where his roles included Director of Marketing (Europe), Manager of Product Development, surgical division, and Software Development Engineer. Furthermore, Mr. Ratini has served as an independent business consultant, providing consulting services and advice to medical technology companies in Switzerland and France.
Ofir Paz, Chief Executive Officer and co-founder of InspireMD, commented, "We are pleased to welcome Robert to InspireMD, as he brings a vast array of skills and expertise to our management team. His appointment is a critical step in our efforts to strengthen and expand the sales and marketing infrastructure for MGuard™ and his experience will help us overcome the challenge of establishing MGuard™ as a significant product in the stent market. We look forward to the strategic contributions and the fresh insights Robert will bring during this exciting time for InspireMD."
"I am very pleased to join InspireMD, as the Company prepares for global commercialization of MGuard™," said Mr. Ratini. "I believe that MGuard™ is an exciting product with the potential of filling a large unmet need and becoming the standard of care for the interventional treatment of Acute MI patients."
Mr. Ratini holds a Master of Computer Sciences from the University of Applied Sciences (HES-SO) in Bienne, Switzerland and a Swiss Federal Diploma of Electronics from Ecole Technique Neuchâtel. In addition, he studied International Marketing at INSEAD in Paris and Management at CQM, Cambridge, USA.
About InspireMD Inc.
InspireMD is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard™. InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is listed on the OTC BB under the ticker symbol "NSPR".
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multi-national companies, (v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K filed with the SEC on March 13, 2012. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.